Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 3Myelodysplastic Syndromes 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Biphenotypic, Acute 1Leukemia 1Blast Crisis 1

Interventions

asciminib 10Cyclophosphamide 9Mycophenolic Acid 7fludarabine 5Whole-Body Irradiation 5nilotinib 4fludarabine phosphate 4Stem Cell Transplantation 4Specimen Handling 4Dasatinib 4olverembatinib 3bosutinib 3Imatinib Mesylate 3Cyclosporine 3venetoclax 2ponatinib 2blinatumomab 2X-Rays 2Thiotepa 2Tacrolimus 2Sirolimus 2Melphalan 2Magnetic Resonance Spectroscopy 2Hematopoietic Stem Cell Transplantation 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Cyclosporins 2Bone Marrow Transplantation 2Blood Component Removal 2Biopsy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × midostaurin × Clear all
NCT02115295 2026-05-20

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

M.D. Anderson Cancer Center

Phase 2 Recruiting
508 enrolled
MyeloidOther hematologic neoplasm

Blast Crisis, Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡